With Glivec, Novartis had found a breakthrough cancer treatment, and it hoped India’s new patent laws would protect its innovative drug. Here’s how a poorly waged patent battle metastasized into an international controversy.
Under palm trees bent by South India’s monsoon winds, this summer hundreds of protesters gathered outside the onion-domed High Court complex in the city of Chennai (formerly known as Madras). Their signs urged Swiss pharmaceutical giant Novartis AG to drop its legal challenge to India’s patent laws. The protesters feared that Indian generic drug manufacturers, which supply the bulk of medicine to the developing world, would be stifled by the stronger protection for innovative drugs that Novartis was suing to impose. “Patients, not patents!” was their cry.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
